212 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 212 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Tumor, Oncology, Cancer, Cell, Clinical, Therapeutics, Therapies, Drug, Anti-Tumor .

Start-ups (31)

Early-stage companies (66)

Established companies (104)

The majority of these companies is located in the following countries.

United States (115)

China (18)

France (15)

Canada (11)

Example Companies

Find companies in your area

Eutilex Eutilex Co. Ltd.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor microenvironment

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

solid tumors, where AhR is constantly activated causing suppression of anti-tumor immune responses. Many cells involved in immunity express AhR. Examples ...

cells and T cells. Activation of AhR in these immune cells causes reduced anti-tumor immunity. During viral infections AhR is activated by viral agents, causing

Tollys

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

specific cytotoxic T lymphocytes (CTL) in the tumor bed, resulting in anti-tumor effects and in-situ auto vaccination against recurrences. Former heterogenous ...

sequence and length. TL-532 showed efficacy in preclinical models to induce anti-tumor response and prevention of recurrences with a good tolerability and a

BioComo BioComo Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

BC-PIV 1 TAV:T cell-signaling anti-tumor virus A NEW TNFRSF SIGNAL ENHANCEMENT SYSTEM 2 Three Antitumor Immune Effects of Antibodies ① Antibodies bind ...

Anti PD-1 antibodies, attacks and kills etc. block this pathway, activate anti-tumor immunity, and attack cancer cells. Feature Fabs of antibodies (Abs) ...

signals enhance anti-tumor activity TNFRSF : tumor necrosis factor receptor superfamily • Future cancer treatments will be focused on anti-tumor immunotherapy ...

Non-toxic Enhancement of Positive Immunity is Key to Next-Generation anti-tumor Immunotherapy Agents • Binding of OX40 or 4-1BB ligand to OX40 or 4-1BB ...

will annihilate any type of solid tumors for treatment. ◆ Stimulation of anti-tumor activity ①signal act ivat ion ②act ivat ion of t umor immunit y OX40L/ ...

41BBL( ) on BC-PIV the envelopes of BC-PIV TAV surfaces * (T cell-signaling anti-tumor virus) ◆ Mechanism of action of "vector-mediated TNFRSF signal activation"

SARS-CoV-2 vaccine development (pdf) 2020-2 Scrip features BC-PIV based new anti-tumor TNFRSF Signal Activator entitled “Japan's BioComo Pursues Novel Ligand ...

Ligand Approach To Immuno-Oncology” 2019-10 New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at Japan Healthcare Venture Summit ...

lead author at Scientific Reports 2019-6 New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at BIO2019 (Philadelphia) 2018-10

Alloplex Biotherapeutics Alloplex Biotherapeutics, LLC

start-up

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

BioConsulting (previously Defined Health). About SUPLEXA cells SUPLEXA cells are anti-tumor effector cells derived from the differential and activation of peripheral ...

cells are comprised of multiple cell types, with many known to possess anti-tumor activity such as natural killer (NK), TCR-gd positive T cells, cytotoxic ...

mechanisms of action and represents an orthogonal approach to anti-tumor cytolysis. The broad anti-tumor cytolytic activity of SUPLEXA cells is specific, with

Immunotherapy Trials Network. About SUPLEXA cells SUPLEXA cells are anti-tumor effector cells derived from the differential and activation of peripheral ...

cells are comprised of multiple cell types, with many known to possess anti-tumor activity such as natural killer (NK), TCR-gd positive T cells, cytotoxic ...

mechanisms of action and represents an orthogonal approach to anti-tumor cytolysis. The broad anti-tumor cytolytic activity of SUPLEXA cells is specific, with

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.